Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy

Pediatric Allergy and Immunology

Volumn 26, Issue 1, 2015, Pages 34-41

  Arroabarren, Esozia ^a   Tabar, Ana I ^a   Echechipía, Susana ^a   Cambra, Koldo ^b   García, Blanca E ^a   Alvarez Puebla, Maria J ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b Fundacion Miguel Servet   (Spain)

Author keywords

Allergen immunotherapy; Asthma; Children; Long term effect; Rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; HOUSE DUST ALLERGEN; PLACEBO;

ARTICLE; ASTHMA; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIZATION; FEMALE; FOLLOW UP; HOUSE DUST ALLERGY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PHASE 4 CLINICAL TRIAL; PHLEUM PRATENSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SKIN TEST; SUBCUTANEOUS IMMUNOTHERAPY; TREATMENT DURATION; VISUAL ANALOG SCALE; ANIMAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DESENSITIZATION; DRUG USE; IMMUNOLOGY; PYROGLYPHIDAE; RESPIRATORY HYPERSENSITIVITY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, DERMATOPHAGOIDES; CHILD; CLINICAL PROTOCOLS; DESENSITIZATION, IMMUNOLOGIC; DRUG UTILIZATION REVIEW; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PROSPECTIVE STUDIES; PYROGLYPHIDAE; RESPIRATORY HYPERSENSITIVITY; SKIN TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923093121     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12296     Document Type: Article

References (30)

1. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011: 127: 18-27.
2. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010: (8):CD001186. doi: 10.1002/14651858.CD001186.pub2.
3. Passalacqua G. Specific immunotherapy: beyond the clinical scores. Ann Allergy Asthma Immunol 2011: 107: 401-6.
4. Larenas-Linnemann DE, Gupta P, Mithani S, Ponda P. Survey on immunotherapy practice patterns: dose, dose adjustments, and duration. Ann Allergy Asthma Immunol 2012: 108: 373-8.
5. 2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010: 65: 1525-30.
6. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011: 127(1 Suppl): S1-55.
7. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, V: duration of the efficacy of immunotherapy after its cessation. Allergy 1996: 51: 430-3.
8. Ali I, Goksal K, Ozan B, Gulsen D. Long-term allergen-specific immunotherapy correlates with long-term allergen allergen-specific tolerance. Adv Ther 2008: 25: 29-36.
9. Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011: 127: 57-63, 63.e1-3.
10. Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off label drug use in paediatric outpatients. Br J Clin Pharmacol 2002: 54: 665-70.
11. Bufe A, Roberts G. Specific immunotherapy in children. Clin Exp Allergy 2011: 41: 1256-62.
12. Calderon MA, Gerth van Wijk R, Eichler I, et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol 2012: 23: 300-6.
13. Larenas-Linnemann DE, Pietropaolo-Cienfuegos DR, Calderón MA. Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. Ann Allergy Asthma Immunol 2011: 107: 407-416.e11.
14. Eichler I, Sala Soriano E. Close collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children. Allergy 2011: 66: 999-1004.
15. Tabar AI, Echechipía S, García BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005: 116: 109-18.
16. Pocock SJ. Methods of Randomization. In: Pocock SJ. Clinical trials: a practical approach. John Wiley & Sons, 1983.
17. International Consensus report on the diagnosis and management of rhinitis. Allergy 1994: 49 (Suppl 19): 1-34.
18. National Institutes of Health 1995 epidemiology. In: Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention (National Institute of Health, National Heart, Lung and Blood Institute and World Health Organisation Workshop Report). Bethesda, MD: National Institutes of Health, 1995 NIH publication no. 95: 3659-60.
19. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Bull World Health Organ 2001: 79: 373-4.
20. Olaguibel JM, Tabar AI, García Figueroa BE, Cortés C. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study. Allergy 1997: 52: 168-78.
21. Olaguíbel JM, Tabar AI, García BE, Martín S, Rico P. Long-term immunotherapy with an optimal maintenance dose of a standardized Dermatophagoides pteronyssinus extract in asthmatic patients. J Investig Allergol Clin Immunol 1999: 9: 110-6.
22. Tabar AI, Lizaso MT, García BE, et al. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Pediatr Allergy Immunol 2008: 19: 67-75.
23. Meltzer EO. Evaluating rhinitis: clinical, rhinomanometric, and cytologic assessments. J Allergy Clin Immunol 1988: 82: 900-8.
24. Aas K. Heterogeneity of bronchial asthma. Allergy 1981: 36: 3-14.
25. Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007: 62: 367-72.
26. American Thoracic Society. Standardization of spirometry. 1994 update. Am J Respir Crit Care Med 1995: 152: 1107-36.
27. European Academy of Allergology and Clinical Immunology. Position paper: allergen standardization and skin tests. Allergy 1993: 48(Suppl 14): 48-82.
28. Röder E, Berger MY, De Groot H, Van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 2008: 19: 197-207.
29. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011: 127: 509-16.e1-5.
30. Stelmach I, Sobocińska A, Majak P, Smejda K, Jerzyńska J, Stelmach W. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol 2012: 109: 274-8.